Daiwa Securities Group
INZY

Daiwa Securities Group’s Inozyme Pharma INZY Stock Holding History

Daiwa Securities Group’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-44
Closed -$1K – 1413
2021
Q3 		$1K Hold
44
– – ﹤0.01% 1270
2021
Q2 		$1K Hold
44
– – ﹤0.01% 1195
2021
Q1 		$1K Hold
44
– – ﹤0.01% 1202
2020
Q4 		$1K Buy
+44
New +$1.05K ﹤0.01% 1182

Other funds holding INZY

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Daiwa Securities Group's INZY Position: Q4 2021 in Review

Daiwa Securities Group sold out of Inozyme Pharma (INZY) in Q4 2021, closing a stake of 44 shares — an estimated $1K sold.

Daiwa Securities Group first reported a position in INZY in Q4 2020 and held it in 4 quarters. The position peaked at $1K in Q3 2021. 51 funds tracked by Wall St. Rank hold INZY as of Q4 2021.

  • Daiwa Securities Group reported no remaining Inozyme Pharma position as of Q4 2021 after selling out during the quarter.
  • Daiwa Securities Group sold 44 Inozyme Pharma shares in Q4 2021, an estimated $1K.
  • Daiwa Securities Group first reported a position in Inozyme Pharma in Q4 2020 and held it in 4 quarters.
  • Daiwa Securities Group's Inozyme Pharma position peaked at $1K in Q3 2021.
  • 51 funds tracked by Wall St. Rank held Inozyme Pharma as of Q4 2021.

Based on Daiwa Securities Group's 13F filing for Q4 2021, filed 3 Feb 2022.